Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective

References

• Taylor WJ, Mease PJ, Adebajo A, et al. Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol 2010;37:1885-91
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-7
   PubMed Web of Science ®Google Scholar
• Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014;74:423-41
   PubMed Web of Science ®Google Scholar
• Kang EJ, Kavanaugh A. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis 2015;6:194-203
   PubMed Web of Science ®Google Scholar
• Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther 2008;10:R17
   PubMed Web of Science ®Google Scholar
• Hoff M, Gulati AM, Romundstad PR, et al. Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trondelag health study (HUNT). Ann Rheum Dis 2015;74:60-4
   PubMed Web of Science ®Google Scholar
• Liu JT, Yeh HM, Liu SY, et al. Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World J Orthop 2014;5:537-43
   PubMedGoogle Scholar
• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 2008;35:1354-8
   PubMed Web of Science ®Google Scholar
• Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum 2016;68:915-23
   Google Scholar
• Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 2002;8:S664-S81; quiz S82–5
   PubMed Web of Science ®Google Scholar
• Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 2010;35:680-9. https://www.ptcommunity.com/journal/article/archives/2010/12/680/burden-psoriatic-arthritis
   PubMedGoogle Scholar
• Bohdanowicz M, Thavaneswaran A, Chandran V, et al. Economic impact of psoriatic Arthritis at a single center in Toronto Ontario. J Rheumatol 2014;41:1542-3
   Google Scholar
• Gladman DD, Yu M, Bohdanowicz M, et al. The economic impact of psoriatic arthritis in Toronto, Ontario. Arthritis Rheum 2014;66:S701-S2
   Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum 2016;68:1060-71
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94
   PubMed Web of Science ®Google Scholar
• Rohekar S, Chan J, Tse SM, et al. 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part II: Specific management recommendations. J Rheumatol 2015;42:665-81
   PubMed Web of Science ®Google Scholar
• Rohekar S, Chan J, Tse SM, et al. 2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. J Rheumatol 2015;42:654-64
   PubMed Web of Science ®Google Scholar
• Soriano ER. Management of psoriatic arthritis: traditional disease-modifying rheumatic agents and targeted small molecules. Rheum Dis Clin North Am 2015;41:711-22
   PubMed Web of Science ®Google Scholar
• Boyd T, Kavanaugh A. Interleukin-17 inhibition in psoriatic arthritis. Clin Exp Rheumatol 2015;33:S119-S23
   PubMedGoogle Scholar
• Cosentyx® Product Monograph [Internet]. Health Canada; Dorval, Quebec. 2016. https://pdf.hres.ca/dpd_pm/00034577.PDF
   Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373:1329-39
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Reimold AM, et al. Secukinumab for long-term treatment of psoriatic arthritis: 2-year follow-up from a phase 3, randomized, double-blind, placebo-controlled study. Arthritis Care Res 2016;69:347-55
   Web of Science ®Google Scholar
• Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis through 3 years: efficacy and safety results from a phase 3 trial [abstract]. Arthritis Rheum 2016;68
   Web of Science ®Google Scholar
• Bojke L, Epstein D, Craig D, et al. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology 2011;50(Suppl 4):iv39-iv47
   PubMed Web of Science ®Google Scholar
• Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15:i–xxi,1-329
   PubMed Web of Science ®Google Scholar
• Bravo Vergel Y, Hawkins NS, Claxton K, et al. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 2007;46:1729-35
   PubMed Web of Science ®Google Scholar
• Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10:iii–iv,xiii–xvi,1-239
   PubMed Web of Science ®Google Scholar
• Cawson MR, Mitchell SA, Knight C, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord 2014;15:26
   PubMed Web of Science ®Google Scholar
• Cummins E, Asseburg C, Prasad M, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ 2012;13:801-9
   PubMed Web of Science ®Google Scholar
• Cummins E, Asseburg C, Punekar YS, et al. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health 2011;14:15-23
   PubMed Web of Science ®Google Scholar
• Graham CN, Gunda P, Miles L, et al. A new cost-effectiveness framework for modeling psoriatic arthritis treatments. Value Health 2016;19:A233-A234
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20
   PubMed Web of Science ®Google Scholar
• Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl 2):ii49-54
   PubMedGoogle Scholar
• NICE Multiple Technology Appraisal - Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs; 2016. London, UK. https://www.nice.org.uk/guidance/ta445/documents/html-content-3
   Google Scholar
• McInnes I, Nash P, Ritchlin C, et al. Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus licensed biologics and apremilast from a network meta-analysis. Ann Rheum Dis 2016;75:348-9
   PubMed Web of Science ®Google Scholar
• Gladman DD, Sampalis JS, Illouz O, et al. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010;37:1898-906
   PubMed Web of Science ®Google Scholar
• Reddy SM, Crean S, Martin AL, et al. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature. Clin Rheumatol 2016;35:2955-66
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Consumer Price Index, historical summary (1996 to 2015). Government of Canada. 2016. Ottawa, Ontario. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ46a-eng.htm
   Google Scholar
• Ontario drug benefit formulary/comparative drug index. Ontario Ministry of Health and Long-Term Care; 2016. Toronto, Ontario. http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx
   Google Scholar
• Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62
   PubMed Web of Science ®Google Scholar
• Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol 2012;51:1432-40
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Alten R, Strand V, et al. The relationship between physical functioning and work for people with psoriatic arthritis: results from a large real-world study in 16 countries. Arthritis Rheum 2016;68
   Google Scholar
• The World Bank, GDP per capita: 1960–2015. World Bank; 2016. Washington, USA. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end =2015&locations=CA&start =1960&view=chart
   Google Scholar
• Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72
   PubMed Web of Science ®Google Scholar
• Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010;163:586-92
   PubMed Web of Science ®Google Scholar
• Statistics Canada: Probability of dying by age and sex, Canada, 2007/2009 period. 2016. Ottawa, Ontario. http://www.statcan.gc.ca/pub/91-209-x/2013001/article/11785/c-g/desc/desc02-eng.htm
   Google Scholar
• Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006
   Google Scholar
• Jaime Caro J, Eddy DM, Kan H, et al. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17:174-82
   PubMed Web of Science ®Google Scholar
• The Dental and Pharmaceutical Benefits Agency (TLV): Cosentyx ingår i högkostnadsskyddet med begränsning. 2016. Stockholm, Sweden. http://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/Cosentyx-ingar-i-hogkostnadsskyddet-med-begransning1/
   Google Scholar
• Nash P, McInnes I, Mease P, et al. Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness versus adalimumab using a matching-adjusted indirect comparison. Arthritis Rheum 2016;68
   Web of Science ®Google Scholar
• Strand V, Mease P, McInnes I, et al. Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness versus infliximab using a matching-adjusted indirect comparison. Arthritis Rheum 2016;68
   Web of Science ®Google Scholar
• McInnes I, Nash P, Mease P, et al. Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus adalimumab up to 48 weeks using a matching-adjusted indirect comparison. Clin Exp Rheumatol 2016;34:782
   Web of Science ®Google Scholar
• Nash P, McInnes I, Mease P, et al. Secukinumab for psoriatic arthritis: comparative effectiveness results versus etanercept up to 24 weeks using a matching-adjusted indirect comparison. Int J Rheum Dis 2016;19:244-5
   Google Scholar
• Coates LC, FitzGerald O, Mease PJ, et al. Development of a disease activity and responder index for psoriatic arthritis—report of the Psoriatic Arthritis Module at OMERACT 11. J Rheumatol 2014;41:782-91
   PubMedGoogle Scholar
• Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986-91
   PubMed Web of Science ®Google Scholar